Allspring Global Investments Holdings LLC decreased its position in shares of MetLife, Inc. (NYSE:MET – Free Report) by 39.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,179 shares of the financial services provider’s stock after selling 27,259 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in MetLife were worth $3,308,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Vermillion & White Wealth Management Group LLC increased its holdings in MetLife by 790.0% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 356 shares of the financial services provider’s stock valued at $29,000 after buying an additional 316 shares in the last quarter. Foster Dykema Cabot & Partners LLC purchased a new position in MetLife in the third quarter valued at $32,000. JPL Wealth Management LLC purchased a new position in MetLife in the third quarter valued at $33,000. Evolution Wealth Management Inc. purchased a new position in MetLife in the second quarter valued at $35,000. Finally, Salomon & Ludwin LLC increased its holdings in MetLife by 95.4% in the third quarter. Salomon & Ludwin LLC now owns 422 shares of the financial services provider’s stock valued at $35,000 after buying an additional 206 shares in the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.
MetLife Stock Up 0.2%
Shares of NYSE MET opened at $71.19 on Wednesday. MetLife, Inc. has a 52-week low of $66.83 and a 52-week high of $83.85. The company’s 50-day simple moving average is $73.40 and its 200-day simple moving average is $77.08. The company has a quick ratio of 0.20, a current ratio of 0.20 and a debt-to-equity ratio of 0.52. The firm has a market cap of $46.42 billion, a price-to-earnings ratio of 15.15, a price-to-earnings-growth ratio of 0.63 and a beta of 0.74.
Wall Street Analyst Weigh In
MET has been the subject of a number of analyst reports. UBS Group upped their price target on MetLife from $94.00 to $98.00 and gave the stock a “buy” rating in a report on Thursday, February 5th. Evercore set a $95.00 price target on MetLife in a report on Tuesday, February 10th. Mizuho set a $100.00 price target on MetLife in a report on Thursday, February 12th. Keefe, Bruyette & Woods reiterated a “moderate buy” rating and set a $87.00 target price on shares of MetLife in a research report on Thursday, March 26th. Finally, Weiss Ratings lowered MetLife from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, MetLife currently has a consensus rating of “Moderate Buy” and a consensus price target of $93.42.
Read Our Latest Stock Report on MET
About MetLife
MetLife, Inc is a global provider of insurance, annuities and employee benefit programs. Headquartered in New York City, the company offers a range of risk protection and retirement solutions to individuals, employers and institutional clients. Its core businesses include life insurance, group benefits, retirement products such as annuities, and supplemental health products including dental and disability coverage.
In addition to traditional life and group insurance, MetLife provides workplace benefits and voluntary products distributed through employer-sponsored programs.
Featured Stories
Want to see what other hedge funds are holding MET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MetLife, Inc. (NYSE:MET – Free Report).
Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.
